Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01006733 · ClinicalTrials.gov registry record · Phase 3
Genetics Informatics Trial (GIFT) of Warfarin to Prevent DVT
A Phase 3 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,598
- Enrollment target
NCT01006733: Completed Phase 3 study, sponsored by Washington University School of Medicine.
NCT01006733 is a Phase 3 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 1,598 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (107% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01006733, a Phase 3 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,598 participants
- Enrollment target
Study Summary
Blood clots contribute to the death of at least 100,000 Americans each year. Because many of these deaths occur suddenly where treatment is impossible, the best treatment is prevention. With this grant, researchers in Missouri, New York, Utah, Illinois, and Texas are developing strategies to improve the safety and effectiveness of clot prevention by customizing a popular blood thinner (warfarin) to each person's genetic and clinical profile. They hypothesize that the use of genetics to guide warfarin therapy will reduce the risk of venous thromboembolism (VTE) postoperatively. They further hypothesize that using a target international normalized ratio (INR) of 1.8 is non-inferior to using a target INR of 2.5 in VTE prevention.
Interventions
- GENETIC Pharmacogenetic
- DRUG Target INR 1.8
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,598 participants |
| Start Date | 2011-03 |
| Est. Completion | 2016-11 |
| Phase | Phase 3 |
What the finished NCT01006733 record still lists
NCT01006733 is an interventional study that assigns participants to a tested intervention. Its 1,598 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (107% higher).
The record links to 0 conditions, and to 2 interventions - of which Pharmacogenetic is the first listed.
NCT01006733 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01006733 about?
NCT01006733 is a clinical study titled "Genetics Informatics Trial (GIFT) of Warfarin to Prevent DVT". Blood clots contribute to the death of at least 100,000 Americans each year. Because many of these deaths occur suddenly where treatment is impossible, the best treatment is prevention. With this grant, researchers in Missouri, New York, Utah, Illinois, and Texas are developing strategies to improve...
What is the current status of trial NCT01006733?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,598 participants. The study started on 2011-03. Estimated completion is 2016-11.
What interventions are being tested in trial NCT01006733?
The interventions under investigation include: Pharmacogenetic (GENETIC), Target INR 1.8 (DRUG).
Who is sponsoring clinical trial NCT01006733?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01006733's enrollment target sits among peer trials
1,598 146th of 2000 higher than 1,855 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00646022 · 1,600 participants
Natural History of Familial Carcinoid Tumor
- NCT03109197 · 1,600 participants
Sudden Unexplained Death in Childhood (SUDC) Registry
- NCT03511118 · 1,600 participants
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- NCT04314401 · 1,600 participants
National Cancer Institute "Cancer Moonshot Biobank"
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia